Sagility accelerates provider growth strategy through Acquisition of Chirok Health

Date: October 21, 2026 The Manager The Manager Listing Department Listing Department National Stock Exchange of India Limited (NSE) BSE Limited (BSE) Exchange Plaza, 5th Floor Phiroze Jeejeebhoy Towers Plot No. C/1, G-Block Dalal Street Bandra-Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code:544282 Symbol: SAGILITY Dear Sir/Madam, Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We wish to inform you that the Board of Directors of the Company at their meeting held on 21st October 2026, have proposed an acquisition/investment by Sagility (US) Holdings Inc., a wholly owned subsidiary of Sagility Limited. Sagility (US) Holdings Inc., has signed a definitive agreement on 21st October 2026, with Chirok Health LLC, the details of which are given as Annexure A to this letter, as required under the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026. Kindly take the above information on your record For Sagility Limited Satishkumar Sakharayapattana Seetharamaiah Company Secretary & Compliance Officer Membership No: A16008 Place: Bengaluru Sagility Limited (Formerly Sagility India Limited) Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India Corporate Identification Number: L72900KA2021PLC150054 Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagility.com Annexure A Details as required under SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sl. Particulars Details 1. Name of the target entity, details in brief Chirok Health LLC such as size, turnover etc. Turnover: US$ 9.0 M (CY2025) here hereafter mentioned as Chirok 2. Whether the acquisition would fall within No related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” 3 Industry to which the entity being acquired Healthcare services / Healthcare Revenue Cycle belongs. Management (RCM), including Clinical Documentation Integrity (CDI) and medical coding services. 4 Objects and impact of acquisition (including The acquisition is intended to strengthen Sagility’s but not limited to, disclosure of reasons for capabilities in the provider segment by adding acquisition of target entity, if its business is specialised Clinical Documentation Integrity (CDI), outside the main line of business of the listed medical coding and revenue optimisation capabilities, entity); complementing Sagility’s existing healthcare services portfolio. 5 Brief details of any governmental or NA regulatory approvals required for the acquisition 6 Indicative time-period for completion of the 21st October 2026 acquisition 7 Consideration - whether cash consideration Cash or share swap or any other form and details of the same 8 Cost of acquisition and/or the price at which Aggregate purchase consideration of upto US$ 32.35 the shares are acquired M, comprising: • Upfront payment of US$ 20.0 M at closing, subject to customary closing adjustments; and Sagility Limited (Formerly Sagility India Limited) Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India Corporate Identification Number: L72900KA2021PLC150054 Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagility.com • Contingent consideration upto US$ 12.35 M, payable subject to achievement of specified performance milestones 9 Percentage of shareholding / control acquired 100% and / or number of shares acquired 10 Brief background about the entity acquired in Chirok Health LLC is a US-based healthcare services terms of products/line of business acquired, company providing Clinical Documentation Integrity date of incorporation, history of last 3 years’ (CDI), medical coding, Revenue Cycle Management turnover, country in which the acquired entity (RCM), and audit and quality assurance services, has presence and any other significant supported by its proprietary CHEMP workflow information (in brief) platform. The Company was incorporated in 2019 and is headquartered in Tennessee, United States. The Company has turnover of approximately USD 12.7 M, USD 8.2 M, and USD 9.0 M for CY2023, CY2024, and CY2025 respectively. Sagility Limited (Formerly Sagility India Limited) Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India Corporate Identification Number: L72900KA2021PLC150054 Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagility.com